Adaptimmune Therapeutics PLC
NASDAQ:ADAP
Adaptimmune Therapeutics PLC
NASDAQ:ADAP
Price:
1.04 USD
-0.95%
Market Closed
Updated:
May 29, 2024
Adaptimmune Therapeutics PLC
Accumulated Depreciation
|
Adaptimmune Therapeutics PLC
Accumulated Depreciation Peer Comparison
Comparables:
CNTA
AUTL
BCYC
IMCR
GNS
Competitive Accumulated Depreciation Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Accumulated Depreciation | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Adaptimmune Therapeutics PLC
NASDAQ:ADAP
|
Accumulated Depreciation
-$48.4m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
|
Accumulated Depreciation
-$462k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Autolus Therapeutics PLC
NASDAQ:AUTL
|
Accumulated Depreciation
-$28.8m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Accumulated Depreciation
-$14.9m
|
CAGR 3-Years
-53%
|
CAGR 5-Years
-47%
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Accumulated Depreciation
-£52.3m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Accumulated Depreciation
-£161.4m
|
CAGR 3-Years
-20%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Adaptimmune Therapeutics PLC's Accumulated Depreciation?
Accumulated Depreciation
-48.4m
USD
-48.4m
USD
Based on the financial report for Mar 31, 2024, Adaptimmune Therapeutics PLC's Accumulated Depreciation amounts to -48.4m USD.
What is Adaptimmune Therapeutics PLC's Accumulated Depreciation growth rate?
Accumulated Depreciation CAGR 3Y
-14%
-14%
Over the last year, the Accumulated Depreciation growth was -26%. The average annual Accumulated Depreciation growth rates for Adaptimmune Therapeutics PLC have been -14% over the past three years .
You don't have any saved screeners yet
